A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Inclusion Criteria

• •Male or female participants, age 18 years or older at screening.
• •Relapsed or refractory CD22-positive ALL.
• •Subjects with Philadelphia chromosome-positive (Ph+) ALL must have failed standard treatment with at least one tyrosine kinase inhibitor.
• •Patients in Salvage 1 with late relapse should be deemed poor candidates for reinduction with initial therapy.
• •Patients with lymphoblastic lymphoma and bone marrow involvement ≥5% lymphoblasts by morphologic assessment.
• •ECOG performance status 0-2.
• •Adequate renal and hepatic function, and negative pregnancy test for women of childbearing potential.